PL2763992T3 - Nowe chiralne N-acylo-5,6,7(8-podstawione)-tetrahydro- [1,2,4]triazolo[4,3-a]pirazyny jako selektywni antagoniści receptora NK-3, kompozycja farmaceutyczna i sposoby stosowania w zaburzeniach, w których pośredniczy receptor NK-3 - Google Patents
Nowe chiralne N-acylo-5,6,7(8-podstawione)-tetrahydro- [1,2,4]triazolo[4,3-a]pirazyny jako selektywni antagoniści receptora NK-3, kompozycja farmaceutyczna i sposoby stosowania w zaburzeniach, w których pośredniczy receptor NK-3Info
- Publication number
- PL2763992T3 PL2763992T3 PL12766991T PL12766991T PL2763992T3 PL 2763992 T3 PL2763992 T3 PL 2763992T3 PL 12766991 T PL12766991 T PL 12766991T PL 12766991 T PL12766991 T PL 12766991T PL 2763992 T3 PL2763992 T3 PL 2763992T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrazines
- triazolo
- tetrahydro
- acyl
- selective
- Prior art date
Links
- 102000002003 Neurokinin-3 Receptors Human genes 0.000 title 2
- 108010040716 Neurokinin-3 Receptors Proteins 0.000 title 2
- 230000001404 mediated effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003216 pyrazines Chemical class 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pregnancy & Childbirth (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11183679 | 2011-10-03 | ||
| EP11183681 | 2011-10-03 | ||
| EP11183692 | 2011-10-03 | ||
| EP11183678 | 2011-10-03 | ||
| US201161543611P | 2011-10-05 | 2011-10-05 | |
| PCT/EP2012/069546 WO2013050424A1 (en) | 2011-10-03 | 2012-10-03 | NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF |
| EP12766991.9A EP2763992B9 (en) | 2011-10-03 | 2012-10-03 | Novel chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, and methods for use in nk-3 receptor mediated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2763992T3 true PL2763992T3 (pl) | 2016-08-31 |
Family
ID=48043185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12766991T PL2763992T3 (pl) | 2011-10-03 | 2012-10-03 | Nowe chiralne N-acylo-5,6,7(8-podstawione)-tetrahydro- [1,2,4]triazolo[4,3-a]pirazyny jako selektywni antagoniści receptora NK-3, kompozycja farmaceutyczna i sposoby stosowania w zaburzeniach, w których pośredniczy receptor NK-3 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9475814B2 (pl) |
| EP (2) | EP3029042A1 (pl) |
| JP (2) | JP6023814B2 (pl) |
| KR (1) | KR102049534B1 (pl) |
| CN (2) | CN105175421B (pl) |
| AU (1) | AU2012320568C1 (pl) |
| BR (1) | BR112014007652B1 (pl) |
| CA (1) | CA2849751C (pl) |
| CY (1) | CY1117773T1 (pl) |
| DK (1) | DK2763992T3 (pl) |
| EA (2) | EA029340B1 (pl) |
| ES (1) | ES2572604T3 (pl) |
| HR (1) | HRP20160396T1 (pl) |
| HU (1) | HUE028858T2 (pl) |
| MX (1) | MX367774B (pl) |
| PL (1) | PL2763992T3 (pl) |
| RS (1) | RS54833B1 (pl) |
| SI (1) | SI2763992T1 (pl) |
| SM (1) | SMT201600164B (pl) |
| WO (1) | WO2013050424A1 (pl) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10065960B2 (en) | 2010-04-02 | 2018-09-04 | Ogeda Sa | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
| CA2793313C (en) | 2010-04-02 | 2018-01-23 | Euroscreen Sa | Nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders |
| CA2849751C (en) | 2011-10-03 | 2019-06-11 | Euroscreen Sa | Chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptormediated disorders and chiral synthesis thereof |
| EP2978766B1 (en) | 2013-03-29 | 2018-12-19 | Ogeda Sa | N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders |
| JP6316932B2 (ja) | 2013-03-29 | 2018-04-25 | オゲダ エス.エー. | 選択的NK−3受容体拮抗薬としての新規なN−アシル−(3位置換)−(8位置換)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン、医薬組成物、NK−3受容体媒介性障害における使用方法 |
| ES2721018T3 (es) | 2013-03-29 | 2019-07-26 | Ogeda S A | N-Acil-(3-sustituido)-(8-metil)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor NK-3, composición farmacéutica, métodos para su uso en trastornos mediados por el receptor de NK-3 |
| US10183948B2 (en) | 2013-03-29 | 2019-01-22 | Ogeda Sa | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
| GB201315846D0 (en) | 2013-09-05 | 2013-10-23 | Imp Innovations Ltd | Method for treating or preventing hot flushes |
| JP6469214B2 (ja) * | 2014-09-25 | 2019-02-13 | オゲダ エス.エー. | N−アシル−(3−置換)−(8−置換)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジンの新規キラル合成 |
| CA2977444A1 (en) * | 2015-03-16 | 2016-09-22 | Ogeda Sa | Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat |
| JP2021014404A (ja) * | 2017-10-13 | 2021-02-12 | アステラス製薬株式会社 | トリアゾロピラジン誘導体の塩及び結晶 |
| MA53721A (fr) | 2018-09-28 | 2021-09-15 | Janssen Pharmaceutica Nv | Modulateurs de la monoacylglycérol lipase |
| JP7644009B2 (ja) | 2018-12-21 | 2025-03-11 | オゲダ エス.エー. | 3-メチル-1,2,4-チアジアゾール-5-カルボヒドラジドまたはそのメチル-d3重水素化形態の合成 |
| CN111499640A (zh) * | 2019-01-31 | 2020-08-07 | 上海医药工业研究院 | 哌嗪并三唑类衍生物的手性拆分方法 |
| CN112272670B (zh) * | 2019-04-16 | 2023-12-12 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
| CA3156100A1 (en) | 2019-09-30 | 2021-04-08 | Janssen Pharmaceutica Nv | Radiolabelled mgl pet ligands |
| CN113527307B (zh) * | 2020-04-20 | 2024-10-11 | 上海翰森生物医药科技有限公司 | 含三唑基的并环类衍生物抑制剂、其制备方法和应用 |
| CN113549074A (zh) * | 2020-04-26 | 2021-10-26 | 上海翰森生物医药科技有限公司 | 含三唑基的并环类衍生物抑制剂、其制备方法和应用 |
| WO2022022680A1 (zh) * | 2020-07-30 | 2022-02-03 | 上海翰森生物医药科技有限公司 | 含氮并环类衍生物抑制剂、其制备方法和应用 |
| JP7746406B2 (ja) * | 2021-04-21 | 2025-09-30 | 長春金賽薬業有限責任公司 | イミダゾール含有縮合環系誘導体、その調製方法及びその医薬上の応用 |
| CN120787232A (zh) * | 2023-03-10 | 2025-10-14 | 山东绿叶制药有限公司 | Nk-3受体拮抗剂化合物、药物组合物、其制备方法和应用 |
| CN116590300A (zh) * | 2023-05-16 | 2023-08-15 | 华中农业大学 | 动物去势用融合基因、表达载体和基因疫苗及其应用 |
| TW202508570A (zh) * | 2023-07-03 | 2025-03-01 | 日商Agc股份有限公司 | 3-甲基-1,2,4-噻二唑-5-卡肼之新穎製造方法 |
| CN121358715A (zh) * | 2023-07-03 | 2026-01-16 | Agc株式会社 | 3-甲基-1,2,4-噻二唑-5-碳酰肼的新型制造方法 |
| EP4628491A1 (en) | 2024-04-05 | 2025-10-08 | Química Sintética, S.A. | Synthesis of intermediates for the preparation of neurokinin-3 receptor antagonists |
| CN118290429B (zh) * | 2024-06-06 | 2024-10-11 | 山东百诺医药股份有限公司 | 非唑奈坦中间体及非唑奈坦的制备方法 |
| CN118878478B (zh) * | 2024-07-11 | 2025-10-14 | 深圳市华先医药科技有限公司 | 一种构建非唑奈坦手性片段的路线及其中间体和制备方法 |
| CN118955563B (zh) * | 2024-10-16 | 2025-02-11 | 上海翰森生物医药科技有限公司 | 一种含氮并环类衍生物的制备方法 |
| CN119775279B (zh) * | 2024-12-20 | 2025-12-30 | 上海皓元医药股份有限公司 | 一种利用手性辅基合成非唑奈坦及其中间体的方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3252483B2 (ja) | 1992-10-20 | 2002-02-04 | 東レ株式会社 | 3環性トリアゾロ誘導体の製造方法 |
| EP0726260A1 (en) | 1995-02-08 | 1996-08-14 | American Cyanamid Company | Herbicidal (1,2,4)thiadiazoles |
| UA56185C2 (uk) * | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
| DE60018707T2 (de) | 1999-01-25 | 2006-02-09 | Smithkline Beecham Corp. | Anti-androgene und verfahren zur behandlung von krankheiten |
| PL350884A1 (en) * | 1999-04-01 | 2003-02-10 | Pfizer Prod Inc | Aminopyrimidines as sorbitol dehydrogenase inhibitors |
| DE60234354D1 (de) * | 2001-08-24 | 2009-12-24 | Univ Yale | Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel |
| EP1490335B1 (en) * | 2002-03-25 | 2007-09-19 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| ES2270143T3 (es) | 2002-08-07 | 2007-04-01 | Novartis Ag | Compuestos organicos como agentes para el tratamiento de condiciones mediadas por aldosterona. |
| MY139563A (en) | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| AR043443A1 (es) | 2003-03-07 | 2005-07-27 | Merck & Co Inc | Procedimiento de preparacion de tetrahidrotriazolopirazinas y productos intermedios |
| US20040214832A1 (en) * | 2003-04-10 | 2004-10-28 | Cuiman Cai | Piperazine derivative renin inhibitors |
| JP2007507504A (ja) * | 2003-09-30 | 2007-03-29 | メルク エンド カムパニー インコーポレーテッド | フェニルピロリジンエーテル系タキキニン受容体拮抗薬 |
| ATE402935T1 (de) * | 2004-02-18 | 2008-08-15 | Astrazeneca Ab | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen |
| GB0509405D0 (en) * | 2005-05-10 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
| JP2009523170A (ja) * | 2006-01-11 | 2009-06-18 | メルク エンド カムパニー インコーポレーテッド | 縮合トリアゾールタキキニン受容体アンダニスト |
| TWI378091B (en) | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
| GB0610680D0 (en) | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| US7943617B2 (en) | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
| EA201000046A1 (ru) | 2007-06-21 | 2011-02-28 | Кара Терапеутикс, Инк. | Замещенные имидазогетероциклы |
| EP2215093B1 (de) | 2007-10-19 | 2011-12-14 | Boehringer Ingelheim International GmbH | Neue piperazino-dihydrothienopyrimidin-derivate |
| RS53602B1 (sr) | 2007-11-29 | 2015-02-27 | Boehringer Ingelheim International Gmbh | DERIVATI AMIDA 6,7-DIHIDRO-5H-IMIDAZO[1,2-α]IMIDAZOL-3-KARBOKSILNE KISELINE |
| WO2009072643A1 (en) * | 2007-12-03 | 2009-06-11 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound and use thereof |
| CN104876921A (zh) * | 2008-01-09 | 2015-09-02 | 阵列生物制药公司 | 作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶 |
| JP2011509962A (ja) | 2008-01-17 | 2011-03-31 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 置換スルホンアミド誘導体 |
| EP2085398A1 (en) | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| EP2090576A1 (en) * | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
| WO2010125102A1 (en) | 2009-04-29 | 2010-11-04 | Glaxo Group Limited | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS |
| GB0907515D0 (en) | 2009-04-30 | 2009-06-10 | Glaxo Group Ltd | Compounds |
| US20120142672A1 (en) | 2009-07-13 | 2012-06-07 | Tatsuki Koike | Heterocyclic compound and use thereof |
| US10065960B2 (en) | 2010-04-02 | 2018-09-04 | Ogeda Sa | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
| CA2793313C (en) | 2010-04-02 | 2018-01-23 | Euroscreen Sa | Nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders |
| CA2849751C (en) | 2011-10-03 | 2019-06-11 | Euroscreen Sa | Chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptormediated disorders and chiral synthesis thereof |
| EP2978766B1 (en) | 2013-03-29 | 2018-12-19 | Ogeda Sa | N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders |
| ES2721018T3 (es) | 2013-03-29 | 2019-07-26 | Ogeda S A | N-Acil-(3-sustituido)-(8-metil)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor NK-3, composición farmacéutica, métodos para su uso en trastornos mediados por el receptor de NK-3 |
| JP6316932B2 (ja) | 2013-03-29 | 2018-04-25 | オゲダ エス.エー. | 選択的NK−3受容体拮抗薬としての新規なN−アシル−(3位置換)−(8位置換)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン、医薬組成物、NK−3受容体媒介性障害における使用方法 |
| JP6469214B2 (ja) | 2014-09-25 | 2019-02-13 | オゲダ エス.エー. | N−アシル−(3−置換)−(8−置換)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジンの新規キラル合成 |
-
2012
- 2012-10-03 CA CA2849751A patent/CA2849751C/en active Active
- 2012-10-03 EA EA201490579A patent/EA029340B1/ru not_active IP Right Cessation
- 2012-10-03 AU AU2012320568A patent/AU2012320568C1/en active Active
- 2012-10-03 DK DK12766991.9T patent/DK2763992T3/en active
- 2012-10-03 EA EA201591204A patent/EA030586B1/ru not_active IP Right Cessation
- 2012-10-03 HR HRP20160396TT patent/HRP20160396T1/hr unknown
- 2012-10-03 WO PCT/EP2012/069546 patent/WO2013050424A1/en not_active Ceased
- 2012-10-03 CN CN201510557452.4A patent/CN105175421B/zh active Active
- 2012-10-03 BR BR112014007652-9A patent/BR112014007652B1/pt active IP Right Grant
- 2012-10-03 KR KR1020147012169A patent/KR102049534B1/ko active Active
- 2012-10-03 ES ES12766991.9T patent/ES2572604T3/es active Active
- 2012-10-03 CN CN201280048708.3A patent/CN103906750B9/zh active Active
- 2012-10-03 SI SI201230520A patent/SI2763992T1/sl unknown
- 2012-10-03 US US14/349,595 patent/US9475814B2/en active Active
- 2012-10-03 MX MX2014004057A patent/MX367774B/es active IP Right Grant
- 2012-10-03 HU HUE12766991A patent/HUE028858T2/hu unknown
- 2012-10-03 EP EP15201386.8A patent/EP3029042A1/en not_active Withdrawn
- 2012-10-03 RS RS20160334A patent/RS54833B1/sr unknown
- 2012-10-03 PL PL12766991T patent/PL2763992T3/pl unknown
- 2012-10-03 JP JP2014533873A patent/JP6023814B2/ja active Active
- 2012-10-03 EP EP12766991.9A patent/EP2763992B9/en active Active
-
2016
- 2016-05-17 CY CY20161100426T patent/CY1117773T1/el unknown
- 2016-06-09 SM SM201600164T patent/SMT201600164B/it unknown
- 2016-07-28 JP JP2016148578A patent/JP6294918B2/ja active Active
- 2016-09-08 US US15/259,922 patent/US10065961B2/en active Active
-
2018
- 2018-07-27 US US16/047,740 patent/US10683295B2/en active Active
-
2020
- 2020-05-21 US US16/880,337 patent/US10941151B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2763992T1 (sl) | Novi kiralni n-acil-5,6,7,(8-substituirani)-tetrahidro-(1,2,4)triazolo (4,3-a)pirazini kot selektivni nk-3 receptor antagonisti, farmacevtski sestavek, in postopki za uporabo v nk-3 posredovanih motnjah | |
| HUS2400012I1 (hu) | N-acil-(3- szubsztituált)-(8- szubsztituált)-5,6-dihidro-[1,2,4]triazolo[4,3-A]pirazinok mint szelektív NK-3 receptor antagonisták, gyógyászati készítmény, eljárások NK-3 receptor által közvetített rendellenességek során történõ alkalmazásra | |
| LT2552920T (lt) | Nauji nk-3 receptoriaus selektyvūs antagonistų junginiai, farmacinė kompozicija ir būdai, skirti naudoti nk-3 receptoriaus sąlygotų sutrikimų gydymui | |
| IL257312A (en) | H1-pyrazolo[b-4,3]pyridine compounds and their therapeutic use | |
| ZA201406149B (en) | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | |
| IL236075A0 (en) | Imidazo [1,2-b] pyridazine kinase inhibitor derivatives, preparations containing them and their uses | |
| IL227496B (en) | Pyrazolo[4,3–b]pyridines are converted as drugs | |
| SG11201405563VA (en) | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof | |
| IL225299A0 (en) | 7-Hydroxy-pyrazolo[1,5-a]pyrimidine compounds and their use as ccr2 receptor antagonists | |
| SG10201408059QA (en) | 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases | |
| ZA201403927B (en) | Spirothienopyran-piperidine derivatives as orl-1 receptor antagonists for their use in the treatment of alcohol dependence and abuse | |
| GB2523481B (en) | Composition for parental administration, method for producing and use thereof | |
| PL2850070T3 (pl) | Pochodne benzo[1,3]dioksyny i ich zastosowanie jako antagonistów LPAR5 |